Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Western blot [1]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 700393 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Phospho-IR/IGF1R (Tyr1162, Tyr1163) Recombinant Rabbit Monoclonal Antibody (97H9L7)
- Antibody type
- Monoclonal
- Antigen
- Synthetic peptide
- Description
- This antibody is predicted to react with bovine, canine, chicken, chimpanzee, equine, mouse, rat, Rhesus monkey , porcine and Xenopus based on sequence homology.
- Antibody clone number
- 97H9L7
- Concentration
- 0.5 mg/mL
Submitted references Mononuclear diploid cardiomyocytes support neonatal mouse heart regeneration in response to paracrine IGF2 signaling.
Harnessing insulin- and leptin-induced oxidation of PTP1B for therapeutic development.
PTP1B inhibition suggests a therapeutic strategy for Rett syndrome.
Shen H, Gan P, Wang K, Darehzereshki A, Wang K, Kumar SR, Lien CL, Patterson M, Tao G, Sucov HM
eLife 2020 Mar 13;9
eLife 2020 Mar 13;9
Harnessing insulin- and leptin-induced oxidation of PTP1B for therapeutic development.
Krishnan N, Bonham CA, Rus IA, Shrestha OK, Gauss CM, Haque A, Tocilj A, Joshua-Tor L, Tonks NK
Nature communications 2018 Jan 18;9(1):283
Nature communications 2018 Jan 18;9(1):283
PTP1B inhibition suggests a therapeutic strategy for Rett syndrome.
Krishnan N, Krishnan K, Connors CR, Choy MS, Page R, Peti W, Van Aelst L, Shea SD, Tonks NK
The Journal of clinical investigation 2015 Aug 3;125(8):3163-77
The Journal of clinical investigation 2015 Aug 3;125(8):3163-77
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of Phospho-IR/IGF1R pTyr1162/1163 in CHO cells transfected with Insulin-stimulated IR (lanes 2, 4, 6) or unstimulated cells (lanes 1, 3, 5) using a Phospho-IR/IGF1R pTyr1162/1163 recombinant rabbit monoclonal antibody (Product # 700393) at a dilution of 1 µg/mL.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 4. INSR is required for neonatal heart regeneration. ( A ) Sirius red staining of P21 hearts after P1 resection, as in Figure 3 . ( B ) Immunofluorescence detection of phosphorylated INSR at 7dpr is eliminated when Igf2 is conditionally mutated; there is no signal in the absence of injury (sham). ( C ) No detectable phosphorylation of IGF1R regardless of injury or Igf2 status in the 7dpr neonatal heart. Cardiomyocytes in B and C were labeled with antibodies for MYL2 (ventricular myosin light chain) or TNC (troponin C), respectively. See similar results at 3dpr for both INSR and IGF1R in Figure 4--figure supplements 1 and 2 . A positive control for pIGF1R antibody quality is shown in Figure 4--figure supplement 3 . ( D ) Western blot using ventricular lysates from P1 uninjured and resected hearts at 3dpr, comparing control to Insr conditional mutants. The phospho-specific antibody recognizes both pINSR and pIGF1R and so is labeled here simply as phospho-R. Antibodies uniquely recognizing total INSR and total IGF1R (both are approx. 95 kDa), and b-actin as a loading comparison, are also shown. The initial phospho-R blot was stripped and reprobed with the t-INSR antibody; a separate blot run at the same time using the same amount of sample was used for t-IGF1R and actin. Figure 4--figure supplement 1. INSR activation after neonatal heart injury. ( A ) Immunostaining for phosphorylated receptor 3dpr, similar result as at 7dpr shown in Figure 4B-C . ( B ) A high magnificati
